Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) Total Long-Term Assets: ¥873.6 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688505 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd SHSE:688505
70 GF Score
Price ¥7.85
GF Value ¥6.32
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Total Long-Term Assets?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co SHSE:688505 -1.26% 70 Total Long-Term Assets is ¥873.6 Mil as of Jun. 2026. GuruFocus rates SHSE:688505 with a GF Score™ of 70/100 and a GF Value™ of ¥6.32 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Total Long-Term Assets for the quarter that ended in Jun. 2026 was ¥873.6 Mil.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Total Long-Term Assets Related Terms

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Total Long-Term Assets Chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 853.23 906.82 1,007.26 979.72 905.13

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Quarterly Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25 Jun26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 979.72 948.02 930.22 905.13 873.61
SHSE:688505
70GF Score
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd SHSE:688505
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of ¥873.6 Mil mean?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) has a Total Long-Term Assets of ¥873.6 Mil as of Jun. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Total Long-Term Assets too high?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Total Long-Term Assets is ¥873.6 Mil. Overall, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Total Long-Term Assets compare to ZTS?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Total Long-Term Assets of ¥873.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Total Long-Term Assets is ¥873.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥6.32, compared to a current price of ¥7.85 — trading 24.2% above its estimated fair value. The current Total Long-Term Assets is ¥873.6 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505), the current Total Long-Term Assets is ¥873.6 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥7.85 is trading 24.2% above its estimated GF Value™ of ¥6.32. GuruFocus considers Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:688505:

  • Total Long-Term Assets: ¥873.6 Mil
  • GF Value™: ¥6.32 vs. price of ¥7.85 (24.2% above fair value)
  • GF Score™: 70/100 with 1 warning sign

No single metric tells the full story. See the SHSE:688505 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Business Description

Other Exchanges 01349:Hong Kong
Address 308 Cailun Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai, CHN, 201210
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
70GF Score

Get the complete analysis for SHSE:688505

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥7.85
Price
¥6.32
GF Value